India's top court dismisses Novartis petition for cancer drug patent

NEW DELHI (REUTERS) - India's highest court has dismissed Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms which are increasingly focusing on India to drive sales.

In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.

Novartis has been fighting since 2006 to win an Indian patent for an amended form of Glivec. In 2009 it took its challenge against a law that bans patents on newer but not radically different forms of known drugs to the Supreme Court.

Join ST's Telegram channel and get the latest breaking news delivered to you.